Skip to main content

Table 1 Baseline characteristics of included studies in this meta-analysis

From: Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients

Study

Year

Country

Study period

Study design

Sample size

Age (years)

Median (range)

Sex (M/F)

Histology

TNM stage

Treatment

Follow-up (months)

Median (range)

Cut-off value of SII

Survival endpoints

Survival analysis

NOS score

Ha, H.

2016

Korea

2004–2009

Retrospective

158

59.6 (31.3–76.2)

103/55

BTC

IV

Chemotherapy

95.3

572.38

OS

Multivariate

7

Hu, X.

2019

China

2012–2017

Retrospective

113

70

75/38

ECC

I–IV

PTBS + 125I

To Sep 2017

456

OS

Univariate

7

Sellers, C. M.

2019

USA

2005–2016

Retrospective

131

65 (57–71)

68/63

ICC

I–IV

Surgery

12

867

OS

Univariate

8

Li, H.

2020

China

2009–2017

Retrospective

530

57.2

256/274

ICC

I–III

Surgery

18.0 (1.0-115.4)

450

OS, RFS

Multivariate

7

Sun, L.

2020

China

2003–2017

Retrospective

142

63

60/82

GBC

I–IV

Surgery

12

600

OS

Multivariate

8

Tsilimigras, D. I.

2020

USA

2000–2017

Retrospective

688

57 (49–65)

416/272

ICC

I–III

Surgery

22.3

1,150

OS, RFS

Multivariate

8

Zhang, Z.

2020

China

2013–2017

Retrospective

128

56.19

70/58

ICC

I–III

Surgery

25.2

1,027

OS, RFS

Multivariate

7

Chen, H.

2021

China

2012–2020

Retrospective

93

62 (32–90)

62/31

GBC

I–III

Surgery

14 (2-60)

824

OS

Multivariate

8

Du, F.

2021

China

2016–2019

Retrospective

60

61 (28–83)

41/19

BTC

IV

Immunotherapy

To Apr 2020

710

OS, PFS

Univariate

6

Li, L.

2021

China

2002–2019

Retrospective

1072

62

414/658

GBC

I–III

Surgery

53.8

510

OS

Multivariate

7

Ren, A.

2021

China

2013–2018

Retrospective

28

51.5 (46.8–60)

25/3

ICC

IV

Liver transplantation

33.5

447.48

OS, RFS

Multivariate

8

Terasaki, F.

2021

Japan

2002–2015

Retrospective

140

71 (39–85)

109/31

ECC

I–III

Surgery

48.2

1,450

OS

Multivariate

8

Di Martino, M.

2022

Italy

2010–2019

Retrospective

232

70

146/86

ECC

I–IV

Surgery

35.8

592

OS, RFS

Univariate

7

  1. M Male, F Female, BTC Biliary tract cancer, ECC Extrahepatic cholangiocarcinoma, ICC Intrahepatic cholangiocarcinoma, GBC Gallbladder cancer, PTBS Percutaneous transhepatic biliary stenting, OS Overall survival, PFS Progression-free survival, RFS Recurrence-free survival, NOS Newcastle-Ottawa Scale